Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542215 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP17A1NR3C1PGRNR3C2 | |
| SCHEMBL2127929 | 0.84 | CYP3A4 (0.55) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL1542558 | 0.84 | CYP3A4 (0.55) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL2130293 | 0.84 | CYP3A4 (0.76) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL1542848 | 0.84 | CYP3A4 (0.76) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL1542785 | 0.83 | CYP3A4 (0.53) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL2129635 | 0.83 | CYP3A4 (0.53) | CYP3A4NR3C1PGRNR3C2KIF11 | |
| SCHEMBL2491304 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP17A1NR3C1PIP4K2APIP4K2B | |
| SCHEMBL2491303 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP17A1NR3C1PIP4K2APIP4K2B | |
| SCHEMBL1764949 | 0.82 | CYP3A4 (0.68) | CYP3A4NR3C1PGRNR3C2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885CYP17A1 2930/4885NR3C1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.